Progyny, Inc. (PGNY) Stock Score, Valuation & Financial Research
Progyny, Inc. is in the Healthcare sector and Medical - Healthcare Plans industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 41/100.
Quick answer for PGNY
Progyny, Inc. currently has a Wall Street Score of 41/100. The stored market price is $27.35. Its financial score is 36/100. Its valuation score is 10/100. These figures are a research snapshot, not a buy or sell recommendation.
What Progyny, Inc. does
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. monik
PGNY financial snapshot
- Wall Street Score:
- 41/100
- Current price:
- $27.35
- Market capitalization:
- $2.14B
- Revenue:
- $1.29B
- Net income:
- $67.7M
- Free cash flow:
- $191.8M
- Cash:
- $132.6M
- Total debt:
- $27.3M
- EPS:
- 0.68
- P/E ratio:
- 40.2x
- Financial score:
- 36/100
- Valuation score:
- 10/100
- Revenue score:
- 18/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $191.8M, showing positive cash generation.
- The balance sheet shows $132.6M of cash versus $27.3M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 10/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 36/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research PGNY
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.